Australia's Telix in focus as Citi signals confidence in prostate cancer drug
BUZZ-Australia's Telix in focus as Citi signals confidence in prostate cancer drug ** Shares of Telix Pharmaceuticals TLX.AX down 2.5% at A$12.69, tracking a 2% drop in the broader healthcare sub-index .AXHJ
** TLX stock in focus after Citi reiterated its "buy" stance, pointing to increased confidence in its lead prostate cancer drug candidate TLX591 following new data
** Citi said trial data showed the drug was generally safe across combinations with standard prostate cancer treatments, with no signs it disrupted current care
** Says at the latest data cut, most patients were still alive and many remained on treatment, suggesting stable outcome so far
** Citi said the results support planned discussions with the U.S. FDA on moving the drug into the next stage of testing
** All 14 analysts rate the stock "buy" or higher; their median PT is A$21.90 – LSEG-compiled data
** Stock up 13.6% this year, including the day's move
(Reporting by Roushni Nair in Bengaluru)
Recent news on Telix Pharmaceuticals
See all newsMorningstar says shares of Australia's Telix Pharmaceuticals undervalued
Australia's Telix in focus as Citi signals confidence in prostate cancer drug
Brief: Telix Announces Collaborations To Explore Psma-Pet Imaging In Emerging Prostate Cancer Treatment Approaches
Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application
Brief: Telix Pharmaceuticals Says TLX101-PX (PIXLUMI®) MAA Accepted In Europe